Allograft, Venous Ulcer
Conditions
Keywords
Compression therapy, Ulcer
Brief summary
Does the use of decellularised dermis allograft in addition to compression therapy promote healing in chronic venous leg ulceration compared to compression therapy alone
Detailed description
Chronic venous ulceration are open wounds on the lower limbs which have been present for at least three months and are caused by a poorly functioning venous system. The affect about 1% of the general population and about 4% of those over 65. The wounds cause pain, reduced movement, and can smell - greatly affecting the quality of life of leg ulcer patients. The standard care for these patients is compression bandaging, which requires changing several times a week by community or district nurses; this drives the high cost of leg ulcer care, which can amount to £2.5 billion per annum. Skin grafting can be used alongside compression bandaging and can help the ulcers heal faster than compression alone. Grafts can be taken from the patient's own skin, from a donor or from tissue engineered skin. An autograft (using own skin) can cause scarring and the need for a formal surgical procedure in theatre so are not suitable for all ulcer patients. Allografts (donor skin) and xenografts (animal skin) have been used successfully, but present similar drawbacks to autografts, plus the potential for the body to reject the graft and disease transmission. Tissue engineered skin has several advantages as it has been processed to remove the cells, and therefore is won't be rejected via the immune response. Human decellularised dermis (DCD) is generated from donated skin from deceased people and processed to remove the cells. It can be glued or sewn onto the skin under local anesthetic, in an out patient setting. DCD has mainly been studied in patients with diabetic foot ulceration and has shown improved healing rates and quality of life. This study will investigate the use of DCD in addition to compression therapy versus compression therapy alone in patients with chronic venous leg ulceration.
Interventions
OTHERdCELL® Human Dermis (decellularised dermal skin allograft - DCD)
DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
OTHERCompression bandaging therapy
Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
Sponsors
University of Edinburgh
Universidad de Granada
University of Manchester
Gloucestershire Hospitals NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
University of Birmingham
NHS Blood and Transplant
Imperial College London
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
It is not possible to mask participants or the research/clinical teams to the treatment strategy as the DCD graft is visible after application for a period of time. However the primary outcome assessments (verification of index ulcer healing visits) will be completed by an independent clinical assessor trained in the assessment of wound healing, who will have no previous involvement with, or knowledge of, the participant's index ulcer treatment and as such will be blind to the randomised treatment strategy (as the DCD is not expected to be visible after 4 weeks).
Intervention model description
Participants will undergo 1:1 web based randomisation to either standard care or the intervention via an automated system. A minimization algorithm using centre, index ulcer size and duration will be used, including a random component to lessen predictability. A separate Randomisation System Description document will contain full details of the cut-offs for index ulcer size and duration, and the probability that the allocation will be switched.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18 years or older (no upper age limit) * The ability to consent to participation * A diagnosis of venous leg ulceration\* (defined as 'colour duplex confirmation of superficial and or deep venous reflux with any break in the skin that has either: a) been present for more than 2 weeks, or b) occurred in a person with a history of venous leg ulceration) * Documented venous incompetence on duplex ultrasound * Index ulcer wound duration of greater than 3 months * Index ulcer wound size ≥ 2 cm2. * ABPI ≥ 0.8 * in light of the Covd-19 pandemic, the use of handheld continuous wave Dopplers will be allowed to diagnose venous disease to allow participants to be recruited from clinic without the need for an imaging appointment
Exclusion criteria
* A diagnosis of sickle cell * Unable to receive one or more of the randomised treatment strategies for any reason at the discretion of the attending clinical team (e.g. known allergies to dCELL dermis preparation components) * A clinically infected ulcer defined as evidence of erythema, cellulitis or systemically unwell * Treatment with biomedical/topical growth factors within previous 30 days * Previous history of an inability to tolerate compression therapy * Foot ulcer (i.e. below the ankle)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion with a healed index ulcer at 12 weeks after randomisation. | 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to index ulcer healing from randomisation | 12 months | — |
| The percentage change in index ulcer area in cm2 at 12 weeks from randomisation | 12 weeks | — |
| The proportion of participants with a healed index ulcer at 12 months from randomisation | 12 months | — |
| The proportion of participants whose index ulcer healed for whom an ulcer recurred at the index site within 12 months from randomisation | 12 months | — |
| Generic quality of life using the EuroQol-5D (EQ-5D) questionnaire | 12 weeks, 6 months and 12 months from randomisation | A health index on a score of 0 to 1 and the participants' self-rated health on a vertical score of zero to 100. Higher scores indicate better quality of life |
| Disease specific quality of life using the Charing Cross Venous Ulcer Questionnaire (CCVUQ) | 12 weeks, 6 months and 12 months from randomisation | Scale 0 to 100, with lower scores indicating better quality of life |
| The cost for each patient, calculated from the healthcare resources used | 12 months | — |
| Incremental cost-effectiveness ratio (ICER) from the EQ-5D questionnaire, with appropriate sensitivity analysis | 12 months | An intervention may be considered cost-effective when its ICER is less than the threshold set by health policy decision-makers. In the UK, the cost-effectiveness threshold is currently in the range £20 000-30 000 per QALY |
Countries
United Kingdom
Outcome results
None listed